Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases.

Rheumatology (Oxford) 2017 04;56(suppl_1):i78-i87

Parque Tecnológico de la Salud, Medical Genomics, Centre Pfizer, University of Granada, Andalusian Regional Government for Genomics and Oncological Research, Granada, Spain.

Omics studies of systemic autoimmune diseases (SADs) in general, and SLE in particular, have delivered isolated information from transcriptome, epigenome, genome, cytokine and metabolome analyses. Such analyses have resulted in the identification of disease susceptibility genes and the description of IFN expression signatures, allowing extensive insight into the mechanisms of disease and the development of new therapies. Access to such technologies allows the recognition of patterns of disease at a pathway level, thereby, to reclassify SLE and other SADs and to develop new therapeutics from a personalized perspective. The use of omic information allows the discovery of correlative patterns involving drugs not currently suspected to be of value in SADs. In this review, we summarize the omics findings for SLE and propose ways of using the data for the identification of new biomarkers, finding new drugs and reclassifying patients not only with SLE, but also with other SADs.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kew339DOI Listing
April 2017
21 Reads

Publication Analysis

Top Keywords

sle sads
8
autoimmune diseases
8
omics studies
8
systemic autoimmune
8
sle
5
therapies access
4
sads review
4
access technologies
4
insight mechanisms
4
mechanisms disease
4
summarize omics
4
disease development
4
review summarize
4
development therapies
4
allowing extensive
4
ifn expression
4
sle propose
4
discovery correlative
4
genes description
4
expression signatures
4

References

(Supplied by CrossRef)

Similar Publications